

SUBSTITUTE FOR FORM IPC/SB/08

ATTY DOCKET NO: KOGANTY=4A

SERIAL NO:
10/511,101

INFORMATION DISCLOSURE

STATEMENT

LIST OF DOCUMENTS CITED BY

APPLICANT



FIRST INVENTOR: KOGANTY, R.

FILING DATE: September 12, 2005

EXAMINER:

ART UNIT: 1643

U.S. PATENT DOCUMENTS (include at least patentee, patent/pub number and issue date)

| EXAM. INITIAL | ID | DOCUMENT NUMBER | FILING, ISSUE OR PUBLICATION DATE MM-DD-YYYY | PATENTEE OR APPLICANT | Relevant Passage(s) | T* |
|------------------|----|-----------------|---|--------------------------|------------------------|----|
| /A.H./ | AA | 4,235,871 | 10-28-1993 | PAPAHADJOPOULOS, et al. | | |
| | AM | 4,837,028 | 02-26-1985 | GEHO et al. | | |
| | AC | 4,837,028 | 06-06-1989 | ALLEN | | |
| | AM | 4,868,155 | 01-18-2000 | DURETTE, et al. | | |
| | AM | 5,019,369 | 05-28-1991 | PRESANT, et al. | | |
| | AF | 5,019,383 | 06-06-1989 | HOPP | | |
| | A7 | 5,744,144 | 04-28-1998 | FINN, et al. | | |
| | AH | 5,837,249 | 11-30-1999 | HEBER-KATZ, et al. | | |
| | AI | 5,871,746 | 02-16-1999 | BOUTILLON, et al. | | |
| | AJ | 5,993,823 | 11-30-1999 | BOUTILLON, et al. | | |
| | AH | 6,013,779 | 01-18-2000 | WONG, et al. | | |
| | AL | 6,015,564 | 01-18-2000 | BOUTILLON, et al. | | |
| | AH | 6,344,203 | 02-05-2002 | SANDRIN, et al. | | |

FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)

| EXAM. INITIAL | ID | COUNTRY CODE & DOCUMENT NUMBER | PUBLICATION DATE MM-DD-YYYY | PATENTEE OR APPLICANT | Relevant Passage(s) | T* |
|------------------|----|-----------------------------------|-----------------------------------|--|------------------------|----|
| /A.H./ | AP | WO 93/21211 | 10-28-1993 | LABORATORIOS MENARINI | | E |
| | AO | WO 95/27505 | 10-19-1995 | BIOMIRA, INC. | | E |
| | AP | WO 01/36433 | 05-25-2001 | BIOMIRA, INC. | | E |
| | AO | WO 02/076485 | 10-03-2002 | BUDZYNSKI | | E |
| | AR | EP 0 093 851 | 11-16-1983 | NEW YORK BLOOD CENTER, INC | | E |
| | AS | EP 0 203 676 | 12-03-1986 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | | E |
| | AT | EP 0 230 893 | 08-05-1987 | BRACCO INDUSTRIA CHIMICA | | E |

EXAMINER /Anne Holleran/

DATE CONSIDERED

08/20/2008

EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

| SUBSTITUTE FOR FORM IPC/SB/08 | | ATTY DOCKET NO: KOGANTY-4A | | SERIAL NO: 10/511,101 | | |
|---|----|--|-----------------------------------|---------------------------|------------------------|------------|
| INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT | | FIRST INVENTOR: KOGANTY, R. | | | | |
| | | FILING DATE: September 12, 2005 | | | | |
| | | EXAMINER: | | ART UNIT: 1643 | | |
| FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country) | | | | | | |
| EXAM. INITIAL | EE | COUNTRY CODE & DOCUMENT NUMBER | PUBLICATION DATE MM-DD-YYYY | PATENTEE OR APPLICANT | Relevant Passage(s) | T* |
| /A.H./ | AU | EP 0 491 628 | 06-24-1992 | PASTEUR INSTITUTE, et al. | | A |
| | AW | EP 0 945 461 | 09-29-1999 | PASTEUR INSTITUTE, et al. | | A |
| | AW | EP 1 065 212 | 01-03-2001 | PASTEUR INSTITUTE, et al. | | A |
| | AX | EP 1 182 210 | 02-27-2002 | BASTERT, Gunter, et al. | | A |
| OTHER DOCUMENTS (include AUTHOR, title, name of publication, volume, pages & date of publication) Please list in alphabetical order. | | | | | | |
| /A.H./ | AY | BROSSART, et al., "Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", <u>BLOOD</u> , vol. 93, no. 12, pp. 4309-4317, June 15, 1999. | | | | |
| | BB | CARMON, et al., "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in D ^{B*/} X β 2 Microglobulin (β 2m) Null Mice Transgenic for a Chimeric HLA-A2.1/D ^{B*} - β 2 Microglobulin Single Chain", <u>INT. J. CANCER</u> , vol. 85, pp. 391-397, 2000. | | | | |
| | BA | DENTON, et al., "Sequential Order of T and B Cell Epitopes Affects Immunogenicity But Not Antibody Recognition of the B Cell Epitope", <u>PEPTIDE RESEARCH</u> , vol. 7, no. 5, pp. 258-264, 1994. | | | | |
| | BB | DIEZ-BARRA, et al., Chemical Abstract, "Solvent-free phase transfer catalysis. Improvements on serine O-alkylation, Database accession no. 127:220955, 1997. | | | | |
| | BC | ENGELMANN, et al., "Identification and Topology of Variant Sequences within Individual Repeat Domains of the Human Epithelial Tumor Mucin MUC1", <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , vol. 276, no. 30, pp. 27764-27769, July 27, 2001. | | | | |
| | BD | GENDLER, et al., "A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas is Made Up of Tandem Repeats", <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , vol. 263, no. 26, pp. 12820-12823, September 15, 1988. | | | | |
| | BE | HEUKAMP, et al., "Identification of Three Non-VNTR MUC1-Derived HLA-A*0201-Restricted T-Cell Epitopes that Induce Protective Anti-Tumor Immunity in HLA-A2/K ^b -Transgenic Mice", <u>INT. J. CANCER</u> , vol. 91, pp. 385-392, 2001. | | | | |
| | BE | HILTBOLD, et al., "Naturally Processed Class II Epitope from the Tumor Antigen MUC1 Primes Human CD4 ⁺ T Cells", <u>CANCER RESEARCH</u> , vol. 58, pp. 5066-5070, November 15, 1998. | | | | |
| | BG | KEIL, et al., "Towards the Development of Antitumor Vaccines: A Synthetic Conjugate of a Tumor-Associated MUC1 Glycopeptide Antigen and a Tetanus Toxin Epitope", <u>ANGEW. CHEM. INT. ED.</u> , vol. 40, no. 2, pp. 366-369, 2001. | | | | |
| EXAMINER | | /Anne Holleran/ | | DATE CONSIDERED | | 08/20/2008 |
| EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | |

* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

| | | | |
|--|----|--|--------------------------|
| SUBSTITUTE FOR FORM IPC/SB/08 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO: KOGANTY=4A | SERIAL NO: 10/511,101 |
| INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT | | FIRST INVENTOR: KOGANTY, R. | |
| | | FILING DATE: September 12, 2005 | |
| | | EXAMINER: | ART UNIT: 1643 |
| OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication) | | | |
| /A.H./ | BH | KUDRYASHOV, et al., "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis ^x conjugates in mice", <u>PNAS</u> , vol. 98, no. 6, pp. 3264-3269, March 13, 2001. | |
| | BI | MARTINON, et al., "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant", <u>THE JOURNAL OF IMMUNOLOGY</u> , vol. 149, no. 10, pp. 3416-3422, November 15, 1992. | |
| | BJ | MEYLAN, et al., "Atom/Fragment Contribution Method for Estimating Octanol-Water Partition Coefficients", <u>JOURNAL OF PHARMACEUTICAL SCIENCES</u> , vol. 84, no. 1, pp. 83-92, January 1995. | |
| | BK | MÖLLER, et al., "NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3", <u>EUR. J. BIOCHEM.</u> , vol. 269, pp. 144-1455, 2002. | |
| | BL | MORTARA, et al., "Selection of Virus Variants and Emergence of Virus Escape Mutants after Immunization with an Epitope Vaccine", <u>JOURNAL OF VIROLOGY</u> , vol. 72, no. 2, pp. 1403-1410, February 1998. | |
| | BM | PETRAKOU, et al., "Epitope Mapping of Anti-MUC1 Mucin Protein Core Monoclonal Antibodies", <u>TUMOR BIOL.</u> , vol. 19(suppl 1), pp. 21-29, 1998. | |
| | BN | REICHEL, et al., "Synthetic carbohydrate-based vaccines: synthesis of an L-glycero-D-manno-heptose antigen-T-epitope-lipopeptide conjugate", <u>CHEM. COMMUN.</u> , pp. 2087-2088, 1997. | |
| | BO | SAUZET, et al., "Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides", <u>VACCINE</u> , vol. 13, no. 14, pp. 1339-1345, 1995. | |
| | BP | SOARES, et al., "Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection", <u>THE JOURNAL OF IMMUNOLOGY</u> , vol. 166, pp. 6555-6563, 2001. | |
| | BQ | SPRINGER, Georg F., "T and Tn, General Carcinoma Autoantigens", <u>SCIENCE</u> , vol. 224, pp. 1198-1206, June 15, 1984. | |
| | BR | TAYLOR-PAPADIMITRIOU, et al., "Molecular aspects of mucins", <u>CANCER REV.</u> , vol. 11-12, pp. 11-24, 1988. | |
| ↓ | BS | TOYOKUNI, et al., "Synthetic Vaccines: Synthesis of a Dimeric Tn Antigen-Lipopeptide Conjugate That Elicits Immune Responses against Tn-Expressing Glycoproteins", <u>J. AM. CHEM. SOC.</u> , vol. 116, pp. 395-396, 1994. | |
| EXAMINER | | /Anne Holleran/ | |
| | | DATE CONSIDERED | 08/20/2008 |
| EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant. | | | |

